… MTA plus cisplatin in chemotherapy-naïve patients with non-small cell lung cancer (NSCLC).
Patients … Thirty-six chemotherapy-naïve patients with NSCLC received 500 mg/m 2 MTA …

… to MTA (n = 147) or ERL (n = 150), which were already evaluable (29 pts too early). The
clinicopathologic patients' … in the MTA and ERL arms, respectively; in 39% and 49% pts in the …

… of MTA with minimal toxicity. Minimally pre-treated patients have tolerated MTA doses of up
… These findings would suggest that patients with borderline nutritional status or known folate …

… We demonstrated that prolonged MTA pretreatment improved the combination therapy’s
efficiency. This effect correlated with the induction of persistent DNA damage, increased …

… pemetrexed with paclitaxel which is another eligible and quite widely tested agent in advanced
NSCLC cancer patients. … In one study, MTA was compared with docetaxel in patients with …

… Pemetrexed (ALIMTA, LY231514, MTA) is a novel … of pemetrexed as second-line therapy for
NSCLC, all patients … There were 44 evaluable patients in the platinum pretreated group. Two …

… in patients with NSCLC compared single-agent pemetrexed versus docetaxel in patients …
and 7.9 months) did not differ between pemetrexed and docetaxel (P = 0.105 and P = 0.226, …

… Patients with a Grade 2 or greater rash were pretreated with … day of, and the day after
receiving subsequent doses of MTA. … TS levels on MTA activity is unknown, but one patient in this …

… , doxorubicin and docetaxel, and the combination of MTA with … of MTA in other cancers is
also under investigation. Trials are underway or planned in which MTA is given to patients with …

… pemetrexed-based combination chemotherapy. The obvious candidate to combine with
pemetrexed is … II study comparing pemetrexed with pemetrexed plus carboplatin in patients with …